Beneficial effect of ovocystatin on the cognitive decline in APP/PS1 transgenic mice.


Journal

Advances in medical sciences
ISSN: 1898-4002
Titre abrégé: Adv Med Sci
Pays: Netherlands
ID NLM: 101276222

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 06 11 2017
revised: 16 04 2018
accepted: 17 08 2018
pubmed: 7 12 2018
medline: 21 11 2019
entrez: 4 12 2018
Statut: ppublish

Résumé

Cystatin C plays an important role in the course of neurodegenerative diseases and has a beneficial effect through inhibiting cysteine proteases and amyloid-β aggregation. It also induces proliferation and autophagy. Cystatin isolated from chicken egg white, called ovocystatin, has been widely used in the medical and pharmaceutical research due to its structural and biological similarities to human cystatin C. The aim of this study was to assess the effect of administering ovocystatin on the development of dementia-specific cognitive deficits in APP/PS1 transgenic mice. The study was conducted on transgenic B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax mice. Ovocystatin was administered to four-month-old transgenic (AD) and wild type (NCAR) mice in drinking water for 24 weeks (at a dose of 40 and 4 μg/ mouse). The locomotor activity and cognitive functions were determined using an actimeter and the Morris water maze test, respectively. The results of the study indicate that ovocystatin has a beneficial effect on the cognitive functions in APP/PS1 transgenic mice. The strongest effects of ovocystatin were found in the group of AD mice, where ovocystatin was administered in drinking water at a dose of 40 μg/mouse (p < 0.05). Mice from the AD group swam statistically significantly further in the target zone during the trial in the Morris water maze compared to the AD (vehiculum) group (p < 0.05). The obtained results encourage further research into the protective effect, which may be used as an adjuvant in the treatment of deteriorating cognitive functions.

Identifiants

pubmed: 30504006
pii: S1896-1126(18)30307-9
doi: 10.1016/j.advms.2018.08.002
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Peptides 0
Presenilin-1 0
ovocystatin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

65-71

Informations de copyright

Copyright © 2018 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

Auteurs

Bartłomiej Stańczykiewicz (B)

Department of Nervous System Diseases, Wroclaw Medical University, Wroclaw, Poland. Electronic address: bartlomiej.stanczykiewicz@umed.wroc.pl.

Marta Jakubik-Witkowska (M)

Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland.

Maria Rutkowska (M)

Department of Pharmacology, Wroclaw Medical University, Wroclaw, Poland.

Antoni Polanowski (A)

Department of Animal Products Technology and Quality Management, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland.

Jakub Gburek (J)

Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Wroclaw, Poland.

Krzysztof Gołąb (K)

Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Wroclaw, Poland.

Katarzyna Juszczyńska (K)

Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Wroclaw, Poland.

Tadeusz Trziszka (T)

Department of Animal Products Technology and Quality Management, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland.

Joanna Rymaszewska (J)

Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH